Mayo Clinic researchers have developed an innovative testing strategy for mesothelioma that could potentially increase the ...

Alnylam Pharmaceuticals ALNY presented new data from its early-stage study of nucresiran (formerly ALN-TTRsc04) for treating ...

Third cohort dose is one million CAR positive cells; ten times higher than the first cohort dose . SAN JOSE, Calif., Nov. 18, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" ...

Novotech, the global full-service clinical CRO, has published a new report, Small Cell Lung Cancer: Global Clinical Trial ...

CABA-201 safety profile suggests favorable risk-benefit with no CRS or ICANS in the majority of patients; low-grade CRS in three of eight patients and one previously reported ICANS event – – ...

The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

In a discussion with the Cobb Institute, Dr. Priscilla Pemu and Tesheia Harris shared insights on how to make clinical trials more inclusive.

The report highlighted a number of barriers to these partnerships ... In August it was also announced that up to 18 new ...

The discussion at AHA emphasised that the FLOW trial established that semaglutide prevents major ... According to ...

Presented data at EADV supporting potential of ESK-001 as differentiated oral treatment in immune-mediated diseases through maximal TYK2 inhibition - - Continued to advance three clinical programs ...

A simplified imaging protocol using just five views still had good accuracy with a median AUROC of 0.85 and normalized mean ...